HER2-Positive Breast Carcinoma — Trials

HER2-Positive Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 140
Recruiting: 73
Ph III recruiting: 15
Growth YoY: +11.5%
Industry share: 19%
Top sponsor: Fudan University
Termination share: 43.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (52)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05036005	Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)(NeoON)	unknown	Phase 4	108	Institut fuer FrauengesundheitOTHER	1	Apr 18, 2023	clinicaltrials

Data updated 23 days agoSource updated Apr 18, 2023source: clinicaltrials